Active Surveillance
ProVent: Open-Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
Phase: 3
Study Product: Sipuleucel-T vs. Active Surveillance
Estimated Study Completion Date: May 2023
ClinicalTrials.gov Identifier: NCT03686683
PSA Relapse
MAP: Muscadine Plus (MPX) In Men With Prostate Cancer
Phase: 3
Study Product: Muscadine Plus
Estimated Study Completion Date: December 2021
ClinicalTrials.gov Identifier: NCT03535675
Initiating ADT
HERO: A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
Phase: 3
Study Product: Relugolix vs. Leuprolide Acetate
Estimated Study Completion Date: July 31, 2020
ClinicalTrials.gov Identifier: NCT03085095
mCRPC
TALAPRO-2: Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Phase: 3
Study Product: Talazoparib with Enzalutamide vs. Placebo with Enzalutamide
Estimated Study Completion Date: November 25, 2024
ClinicalTrials.gov Identifier: NCT03395197
PROpel: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Phase: 3
Study Product: Olaparib with Abiraterone Acetate vs. Placebo with Abiraterone Acetate
Estimated Study Completion Date: August 17, 2022
ClinicalTrials.gov Identifier: NCT03732820
REFMAL 435: A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
Phase: 1
Study Product: AZD4635 vs. AZD4635 with Durvalumab vs. AZD4635 with Abiraterone Acetate vs. AZD4635 with Enzalutamide
Estimated Study Completion Date: May 13, 2020
ClinicalTrials.gov Identifier: NCT03085095
QUEST: A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase: 1b/2
Study Product: Niraparib with JNJ-63723283 vs. Niraparib with Abiraterone Acetate
Estimated Study Completion Date: August 31, 2021
ClinicalTrials.gov Identifier: NCT03431350
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Phase: 1b/2
Study Product: CPI-1205 with Enzalutamide vs. CPI-1205 with Abiraterone Acetate
Estimated Study Completion Date: August 2020
ClinicalTrials.gov Identifier: NCT03480646
KEYNOTE-365: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer
Phase: 1b/2
Study Product: Pembrolizumab with Olaparib vs. Pembrolizumab with Abiraterone Acetate
Estimated Study Completion Date: May 18, 2022
ClinicalTrials.gov Identifier: NCT02861573
Galahad: An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Phase: 2
Study Product: Niraparib
Estimated Study Completion Date: February 28, 2020
ClinicalTrials.gov Identifier: NCT02854436
TALAPRO-1: A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
Phase: 2
Study Product: Talazoparib
Estimated Study Completion Date: March 3, 2022
ClinicalTrials.gov Identifier: NCT03148795
VISION: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Phase: 3
Study Product: 177Lu-PSMA-617 vs. Standard of care
Estimated Study Completion Date: May 2021
ClinicalTrials.gov Identifier: NCT03511664
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember to talk to your healthcare providers first before making decisions about your plan of care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study. To learn more about our trials, call Stacey at (843) 449-1010 ext. 268 or email us by filling out the form below.